Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Jacks

Urology Pine Bluff, AR Medical Doctor

NPI 1093735110 CMS profile 185155

4303 S Mulberry St, Pine Bluff, AR 71603

Open in the dashboard

General payments

$125,169

31 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$253,000

5 holdings reported · through program year 2025

Through program year 2025, David Jacks of Pine Bluff, AR is reported in the CMS Open Payments database as having received $125,169 across 31 general payments and $0 in research payments paid to them. They also declared ownership or investment interests valued at $253,000 across 5 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $27 1
2024 General $13,500 1
2023 General $34 1
2022 General $24,027 3
2021 General $22,648 3
2020 General $26,637 9
2019 General $38,296 13
2023 Ownership $31,000 1
2022 Ownership $48,000 1
2021 Ownership $45,000 1
2020 Ownership $53,000 1
2019 Ownership $76,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Jacks
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to David Jacks were reported at $27. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year David Jacks Urology median Middle half National median
2019 $38,296 $480 $147–$1,201 $163
2020 $26,637 $246 $87–$645 $114
2021 $22,648 $358 $111–$1,000 $132
2022 $24,027 $476 $143–$1,263 $149
2023 $34 $560 $168–$1,461 $160
2024 $13,500 $563 $170–$1,464 $164
2025 $27 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cryo Specialty Medical, LLC $124,539 6 payments
  2. Pfizer Inc. $135 7 payments
  3. Boston Scientific Corporation $109 1 payment
  4. COMSORT, Inc $100 1 payment
  5. Myriad Genetic Laboratories, Inc. $87 5 payments
  6. Ferring Pharmaceuticals Inc. $54 4 payments
  7. Astellas Pharma US Inc $42 2 payments
  8. Sumitomo Pharma America, Inc. $34 1 payment
  9. Stryker Corporation $27 1 payment
  10. Coloplast Corp $15 1 payment
  11. Other $27 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Current or prospective ownership or investment interest $111,000 4 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $13,500 1 payment
  3. Food and Beverage $555 24 payments
  4. Consulting Fee $100 1 payment
  5. Education $14 1 payment
Products named General payments · program years 2019–2025
  1. XTANDI $177 9 payments
  2. AMS 700 CXR RTE KIT $109 1 payment
  3. KEYTRUDA $100 1 payment
  4. BRACAnalysis CDx $73 4 payments
  5. NOCDURNA $41 3 payments
  6. ORGOVYX $34 1 payment
  7. 1788 $27 1 payment
  8. NA $27 1 payment
  9. SPEEDICATH $15 1 payment
  10. Axonics r-SNM System $14 1 payment
  11. Other $39 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

1,154

Median for Urology: 1,053

Drug cost

$137,083

Median for Urology: $101,464

Branded share of claims

2.8%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lupron Depot Leuprolide Acetate Brand 17 $101,580
Myrbetriq Mirabegron Brand 15 $13,090
Tamsulosin Hcl Generic 550 $7,951
Dutasteride Generic 205 $5,507
Silodosin Generic 37 $3,432
Finasteride Generic 276 $2,721
Estradiol Generic 16 $1,586
Trimethoprim Generic 16 $901
Doxycycline Hyclate Generic 22 $315

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$5,607

Medicare's payments for the services billed

Medicare patients

27

Average age 74

Services billed

52

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Cancer 56%
Arthritis 48%
Diabetes 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

31 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record